Latest Chelsea Therapeutics International (CHTP) H
Post# of 3
Posted On: 03/12/2014 7:20:48 PM
Latest Chelsea Therapeutics International (CHTP) Headlines
Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:41PM CDT
Chelsea Therapeutics International Ltd. (CHTP) reported fourth quarter 2013 loss of 7 cents per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 3 cents per share.
Chelsea Therapeutics Reports Fourth Quarter and Full-Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:25PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31, 2013.
'Mad Money' Lightning Round: Zynga Can Go Higher
at The Street - Sat Mar 08, 5:00AM CST
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
10.9% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Fri Mar 07, 10:04AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 2 months, Chelsea Therapeutics International has returned 10.93% as of today's recent price of $5.58.
Chelsea Therapeutics International Shares Up 14.3% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Fri Feb 28, 9:26AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 1 month, Chelsea Therapeutics International has returned 14.32% as of today's recent price of $5.75.
Chelsea Therapeutics Joins NORD in Promoting Awareness for Rare Disease Day
GlobeNewswire - Fri Feb 28, 6:00AM CST
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), supports raising awareness for Rare Disease Day as a member of National Organization for Rare Disorders (NORD).
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:25AM CST
Champions weren't just basking in glory at the Sochi Winter Olympic games this week. The world of health care produced quite a few stocks deserving gold medals in their own way. Breaking news about a big acquisition propelled one of our humongous...
Chelsea Therapeutics International Ltd: FDA Approval Just the First Hurdle
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 5:30PM CST
Chelsea's Northera, a blood pressure boosting treatment designed to help prevent fainting, finally got the FDA's go-ahead after taking shareholders on a roller coaster ride over the past few years that included a perilous fall in 2012 and an...
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Company news for February 20, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 9:06AM CST
Companies in the News are: LZB,CHTP,NBR,CF
3 Stocks Soaring Higher on These Drug Successes
David Williamson, The Motley Fool - Motley Fool - Wed Feb 19, 6:00PM CST
The biotech space had several winners today, and in this segment from Wednesday's Market Checkup , Motley Fool health care analyst David Williamson takes a look at which stocks popped in this space today, and what drove them through the roof. ...
CHTP's Northera Gains FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 5:20PM CST
Chelsea Therapeutics gained accelerated approval from the FDA for Northera for the treatment of symptomatic neurogenic orthostatic hypotension
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Chelsea Therapeutics International Set to Possibly Pullback After Yesterday's Rally of 24.44%
Comtex SmarTrend(R) - Wed Feb 19, 4:27PM CST
Chelsea Therapeutics International (NASDAQ:CHTP) traded in a range yesterday that spanned from a low of $5.95 to a high of $6.83. Yesterday, the shares gained 24.4%, which took the trading range above the 3-day high of $5.63 on volume of 44.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Zale, Chelsea Therapeutics, and Nabors Industries Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 19, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Today marked the second straight day of abysmal housing data,...
Chelsea Therapeutics Posts Wider Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:41PM CDT
Chelsea Therapeutics International Ltd. (CHTP) reported fourth quarter 2013 loss of 7 cents per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 3 cents per share.
Chelsea Therapeutics Reports Fourth Quarter and Full-Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:25PM CDT
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31, 2013.
'Mad Money' Lightning Round: Zynga Can Go Higher
at The Street - Sat Mar 08, 5:00AM CST
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
10.9% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Fri Mar 07, 10:04AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 2 months, Chelsea Therapeutics International has returned 10.93% as of today's recent price of $5.58.
Chelsea Therapeutics International Shares Up 14.3% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Fri Feb 28, 9:26AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 1 month, Chelsea Therapeutics International has returned 14.32% as of today's recent price of $5.75.
Chelsea Therapeutics Joins NORD in Promoting Awareness for Rare Disease Day
GlobeNewswire - Fri Feb 28, 6:00AM CST
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), supports raising awareness for Rare Disease Day as a member of National Organization for Rare Disorders (NORD).
This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 22, 11:20AM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Feb 22, 7:25AM CST
Champions weren't just basking in glory at the Sochi Winter Olympic games this week. The world of health care produced quite a few stocks deserving gold medals in their own way. Breaking news about a big acquisition propelled one of our humongous...
Chelsea Therapeutics International Ltd: FDA Approval Just the First Hurdle
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 5:30PM CST
Chelsea's Northera, a blood pressure boosting treatment designed to help prevent fainting, finally got the FDA's go-ahead after taking shareholders on a roller coaster ride over the past few years that included a perilous fall in 2012 and an...
New Sears Appliance & Hardware Store Opens in Huntsville
GlobeNewswire - Fri Feb 21, 2:30PM CST
Sears Hometown and Outlet Stores, Inc. (Nasdaq:SHOS) announces the opening of a new Sears Appliance & Hardware Store located at 1702 11 Street in Huntsville, Texas.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Company news for February 20, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 9:06AM CST
Companies in the News are: LZB,CHTP,NBR,CF
3 Stocks Soaring Higher on These Drug Successes
David Williamson, The Motley Fool - Motley Fool - Wed Feb 19, 6:00PM CST
The biotech space had several winners today, and in this segment from Wednesday's Market Checkup , Motley Fool health care analyst David Williamson takes a look at which stocks popped in this space today, and what drove them through the roof. ...
CHTP's Northera Gains FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 5:20PM CST
Chelsea Therapeutics gained accelerated approval from the FDA for Northera for the treatment of symptomatic neurogenic orthostatic hypotension
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Feb 19, 5:13PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Chelsea Therapeutics International Set to Possibly Pullback After Yesterday's Rally of 24.44%
Comtex SmarTrend(R) - Wed Feb 19, 4:27PM CST
Chelsea Therapeutics International (NASDAQ:CHTP) traded in a range yesterday that spanned from a low of $5.95 to a high of $6.83. Yesterday, the shares gained 24.4%, which took the trading range above the 3-day high of $5.63 on volume of 44.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Zale, Chelsea Therapeutics, and Nabors Industries Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 19, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Today marked the second straight day of abysmal housing data,...
(0)
(0)Chelsea Therapeutics International (CHTP) Stock Research Links
Scroll down for more posts ▼